company:novo-nordisk
Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:news
category:news
VK2735's manufacturing alliance with CordenPharma
Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
category:news
BRP - a new GLP1-like peptide
We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.
company:hims
HIMS ends compounded Semaglutide offering
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
chemical:semaglutide
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
country:mexico
Mexico and GLP1s
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:news
Ozempic approved for Chronic Kidney Disease
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
company:novo-nordisk
Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
category:news
The battle for compounded GLP1 continues
The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.
government
Government Price negotiations on Ozempic and Wegovy
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:side-effects
Pancreatitis and Gallstones after massive weight loss
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:news
Robert F. Kennedy Jr vs GLP1
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?